Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
暂无分享,去创建一个
I. Melero | F. Guillén-Grima | J. Pérez-Gracia | V. Segura | C. Prior | A. Calvo | I. Gil-Bazo | A. Gúrpide | F Guillén-Grima | V Segura | A. Panizo | A Panizo | J L Perez-Gracia | C Prior | A Gonzalez | I Melero | E Grande-Pulido | A Gurpide | I Gil-Bazo | A Calvo | A. González | E. Grande-Pulido | F. Guillen-Grima | Ignacio Melero | Álvaro González | Victor Segura | Ignacio Gil-Bazo | Alfonso Calvo
[1] R. Motzer,et al. Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) , 2008 .
[2] R. Figlin,et al. Chemokines as therapeutic targets in renal cell carcinoma , 2008, Expert review of anticancer therapy.
[3] C. Sheehan,et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] M. Michaelson,et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] T. Hagemann,et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.
[6] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[7] Louette R. Johnson Lutjens. Research , 2006 .
[8] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[9] S. Rafii,et al. Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.
[10] M. Gore,et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of Clinical Oncology.
[11] J. Christensen,et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy , 2007, Proceedings of the National Academy of Sciences.
[12] I. García-Ribas,et al. The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research , 2002, Cancer.
[13] Valérie Ferreira,et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. , 2008, European journal of cancer.
[14] T. Choueiri,et al. Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy , 2007, Cancer.
[15] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[16] B. Ramaswamy,et al. Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients , 2006, Clinical Cancer Research.
[17] Kenya Yamaguchi,et al. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. , 2007, Urology.
[18] Robert A. Weinberg,et al. Stromal Fibroblasts in Cancer: A Novel Tumor-Promoting Cell Type , 2006, Cell cycle.
[19] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[20] J. Manola,et al. Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor , 2007, Clinical Cancer Research.
[21] E. Small,et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[23] T. Shono,et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis , 1997, Molecular and cellular biology.
[24] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[25] H J Keselman,et al. Controlling the rate of Type I error over a large set of statistical tests. , 2002, The British journal of mathematical and statistical psychology.
[26] B. Rini,et al. Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). , 2008 .
[27] C. Porta,et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study , 2008 .
[28] M. Kattan,et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma , 2008, Cancer.
[29] S. Loening,et al. Matrix‐metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma , 2000, International journal of cancer.
[30] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[31] John Smeraglia,et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.
[32] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[33] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[34] Y. Tan,et al. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. , 1994, The Journal of biological chemistry.
[35] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[36] A. Cnaan,et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Y. Benjamini,et al. On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics , 2000 .
[38] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] T. Guo,et al. Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma. , 2007, Cancer genetics and cytogenetics.
[40] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.